0VQA logo

Viking Therapeutics LSE:0VQA Stock Report

Last Price

US$42.31

Market Cap

US$4.7b

7D

2.8%

1Y

121.6%

Updated

26 Dec, 2024

Data

Company Financials +

Viking Therapeutics, Inc.

LSE:0VQA Stock Report

Market Cap: US$4.7b

0VQA Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. More details

0VQA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 79.72% per year

Risk Analysis

Earnings are forecast to decline by an average of 8.1% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the UK market

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Viking Therapeutics, Inc. Competitors

Genus

LSE:GNS

UK£1.0b

Oxford Biomedica

LSE:OXB

UK£450.2m

PureTech Health

LSE:PRTC

UK£370.6m

Avacta Group

AIM:AVCT

UK£181.1m

Price History & Performance

Summary of share price highs, lows and changes for Viking Therapeutics
Historical stock prices
Current Share PriceUS$42.31
52 Week HighUS$99.30
52 Week LowUS$17.44
Beta0.88
1 Month Change-20.13%
3 Month Change-32.16%
1 Year Change121.60%
3 Year Change771.55%
5 Year Change486.90%
Change since IPO186.68%

Recent News & Updates

Recent updates

Shareholder Returns

0VQAGB BiotechsGB Market
7D2.8%-0.2%0.5%
1Y121.6%-25.8%2.7%

Return vs Industry: 0VQA exceeded the UK Biotechs industry which returned -25% over the past year.

Return vs Market: 0VQA exceeded the UK Market which returned 2.7% over the past year.

Price Volatility

Is 0VQA's price volatile compared to industry and market?
0VQA volatility
0VQA Average Weekly Movement10.5%
Biotechs Industry Average Movement7.0%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.5%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0VQA's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0VQA's weekly volatility has decreased from 20% to 10% over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
201231Brian Lianwww.vikingtherapeutics.com

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

Viking Therapeutics, Inc. Fundamentals Summary

How do Viking Therapeutics's earnings and revenue compare to its market cap?
0VQA fundamental statistics
Market capUS$4.72b
Earnings (TTM)-US$99.15m
Revenue (TTM)n/a

0.0x

P/S Ratio

-48.0x

P/E Ratio

Is 0VQA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0VQA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$99.15m
Earnings-US$99.15m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.89
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 0VQA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 06:37
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Viking Therapeutics, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG